Upstream Bio (UPB) Projected to Post Earnings on Thursday

Upstream Bio (NASDAQ:UPB) is projected to post its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Upstream Bio to post earnings of ($0.62) per share for the quarter.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($6.38). The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.83 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Upstream Bio Trading Up 4.1 %

Upstream Bio stock opened at $10.25 on Thursday. Upstream Bio has a 52-week low of $9.29 and a 52-week high of $29.46. The business’s 50 day simple moving average is $16.86.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. began coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 price objective for the company. William Blair initiated coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Piper Sandler started coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued a “buy” rating for the company.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.